Wonbiogen Co.,Ltd. Logo

Wonbiogen Co.,Ltd.

Develops and manufactures advanced wound care solutions and medical materials.

307280 | KO

Overview

Corporate Details

ISIN(s):
KR7307280008
LEI:
Country:
South Korea
Address:
경상북도 구미시 1공단로5길 56 ㈜원바이오젠, 구미시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 2006, Wonbiogen Co., Ltd. is a bio-venture company specializing in the research, development, and manufacturing of advanced medical materials. The company's primary focus is on science-driven, advanced wound care solutions. Its product portfolio includes polyurethane foam dressings, hydrocolloid dressings, and soft silicone adhesive products under brands such as MEDISORB and RENODERM. These products are designed to treat a wide range of wounds, from cuts and burns to surgical sites and chronic ulcers. Wonbiogen leverages its expertise in developing highly biocompatible medical macromolecules to create innovative medical supplies and also offers OEM services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 00:00
Share Issue/Capital Change
[기재정정]주식소각결정
Korean 13.0 KB
2025-08-26 00:00
Regulatory Filings
신규시설투자등(자율공시)
Korean 7.5 KB
2025-08-25 00:00
Legal Proceedings Report
불성실공시법인미지정 (지정유예)
Korean 5.5 KB
2025-08-19 00:00
Share Issue/Capital Change
주식소각결정
Korean 9.9 KB
2025-08-13 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-08-01 00:00
Legal Proceedings Report
불성실공시법인지정예고 (공시불이행)
Korean 4.9 KB
2025-07-07 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.2 KB
2025-07-07 00:00
Legal Proceedings Report
소송등의판결ㆍ결정
Korean 5.3 KB
2025-05-23 00:00
Delisting Announcement
주권매매거래정지해제 (액면병합 주권 변경상장)
Korean 4.3 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-29 00:00
Delisting Announcement
주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
Korean 4.6 KB
2025-03-31 00:00
AGM Information
정기주주총회결과
Korean 21.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 441.3 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.6 KB

Automate Your Workflow. Get a real-time feed of all Wonbiogen Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Wonbiogen Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Wonbiogen Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.